Impact of catecholamines on the QTc interval in patients at high risk of sudden death.
Mc Bride
Brian F
BF
John A. Oates, MD Institute for Experimental Therapeutics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Kalus
James S
JS
Guertin
Danette C
DC
Dale
Krista M
KM
Kluger
Jeffrey
J
White
C Michael
CM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D017147:Defibrillators, Implantable; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects*; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D006331:Heart Diseases / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D008133:Long QT Syndrome / Q000150:complications; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000494:pharmacology*; D012306:Risk
D000319:Adrenergic beta-Antagonists; D009638:Norepinephrine; D004837:Epinephrine